{"id":"sodium-hyaluronate-0-18","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Mild ocular discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sodium hyaluronate is a naturally occurring polysaccharide that acts as a humectant and lubricant on the eye surface. It binds water and forms a protective layer over the cornea and conjunctiva, reducing friction and providing sustained hydration. This mechanism makes it effective for treating dry eye disease and protecting the ocular surface during and after ophthalmic procedures.","oneSentence":"Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:33.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Ocular surface protection during ophthalmic surgery"}]},"trialDetails":[{"nctId":"NCT04702776","phase":"PHASE4","title":"Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-12-09","conditions":"Dry Eye","enrollment":182},{"nctId":"NCT05865379","phase":"NA","title":"Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"TRB Chemedica International SA","startDate":"2026-03","conditions":"Dry Eye Disease","enrollment":80},{"nctId":"NCT03697876","phase":"PHASE1","title":"Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-08-20","conditions":"Dry Eye Syndromes","enrollment":32},{"nctId":"NCT03368404","phase":"NA","title":"A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye","status":"COMPLETED","sponsor":"Laboratoire Chauvin","startDate":"2017-11-09","conditions":"Dry Eye","enrollment":92},{"nctId":"NCT06163105","phase":"NA","title":"The Effect of Gland Expression on the Regeneration of Meibomian Gland","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-10-03","conditions":"Meibomian Gland Dysfunction","enrollment":64},{"nctId":"NCT06860659","phase":"PHASE4","title":"Efficacy of 0.28% Sodium Hyaluronate Eye Drops in Patient with Moderate to Severe Dry Eye","status":"ENROLLING_BY_INVITATION","sponsor":"Department of Medical Services Ministry of Public Health of Thailand","startDate":"2024-09-01","conditions":"Dry Eye Disease (DED), Tear Break-Up Time, Tear Disorder","enrollment":84},{"nctId":"NCT06851364","phase":"PHASE2","title":"Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants","status":"COMPLETED","sponsor":"International Islamic University Malaysia","startDate":"2022-10-30","conditions":"Dry Eye","enrollment":45},{"nctId":"NCT03031327","phase":"NA","title":"Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2017-06-17","conditions":"Ocular Discomfort","enrollment":30},{"nctId":"NCT02507934","phase":"NA","title":"Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2015-06-26","conditions":"Dry Eye Syndrome","enrollment":40},{"nctId":"NCT02975102","phase":"NA","title":"A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye","status":"COMPLETED","sponsor":"Laboratoire Chauvin","startDate":"2017-03-01","conditions":"Dry Eye","enrollment":87},{"nctId":"NCT05724056","phase":"NA","title":"Idroflog® for Treatment of Dry Eye Disease (IDROFLOG)","status":"UNKNOWN","sponsor":"Alfa Intes Industria Terapeutica Splendore s.r.l.","startDate":"2023-03-01","conditions":"Dry Eye Disease","enrollment":130},{"nctId":"NCT03803748","phase":"NA","title":"A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi®","status":"COMPLETED","sponsor":"SIFI SpA","startDate":"2019-07-17","conditions":"Dry Eye Syndromes","enrollment":96},{"nctId":"NCT05429229","phase":"PHASE2","title":"Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Adolfo Daniel Rodriguez-Carrizalez","startDate":"2021-11-01","conditions":"Dry Eye Syndromes, Diabetic Retinopathy, Oxidative Stress","enrollment":78},{"nctId":"NCT03803722","phase":"NA","title":"To Demonstrate the Non-inferiority of Eyestil Protection® Compared to Vismed® in Terms of Clinical Performance","status":"TERMINATED","sponsor":"SIFI SpA","startDate":"2019-07-08","conditions":"Dry Eye Syndrome","enrollment":21},{"nctId":"NCT03656484","phase":"PHASE2","title":"New Periodontitis Treatment Based on Hyaluronic Acid and Melatonin","status":"COMPLETED","sponsor":"Concordia Dent Srl","startDate":"2019-01-15","conditions":"Chronic Periodontitis","enrollment":50},{"nctId":"NCT03223909","phase":"PHASE4","title":"Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2016-10-13","conditions":"Dry Eye Syndrome","enrollment":326},{"nctId":"NCT03161080","phase":"NA","title":"Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-02-09","conditions":"Dry Eye Syndromes","enrollment":60},{"nctId":"NCT03524157","phase":"PHASE1","title":"Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-07-17","conditions":"Dry Eye Syndromes, Lubricant Allergy, Tear Disorder","enrollment":30},{"nctId":"NCT02117687","phase":"PHASE4","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05-14","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":80},{"nctId":"NCT01791426","phase":"NA","title":"A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye","status":"WITHDRAWN","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT01382225","phase":"PHASE3","title":"Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-07","conditions":"Dry Eye Syndrome","enrollment":1936},{"nctId":"NCT00938704","phase":"PHASE4","title":"Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-06","conditions":"Dry Eye Syndromes","enrollment":71},{"nctId":"NCT00987727","phase":"PHASE4","title":"Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Dry Eye Syndromes, Keratoconjunctivitis Sicca","enrollment":82},{"nctId":"NCT01363414","phase":"NA","title":"Sodium Hyaluronate and Wavefront Aberrations in Dry Eyes","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2007-01","conditions":"Dry Eye","enrollment":50},{"nctId":"NCT01284439","phase":"NA","title":"Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2011-01","conditions":"Ocular Surface Disease, Glaucoma","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VISMED® Multi","Vismed®"],"phase":"marketed","status":"active","brandName":"sodium hyaluronate 0.18%","genericName":"sodium hyaluronate 0.18%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium hyaluronate is a viscoelastic substance that lubricates and protects the ocular surface by mimicking natural tear film. Used for Dry eye disease, Ocular surface protection during ophthalmic surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}